K
Keith A. Baggerly
Researcher at University of Texas MD Anderson Cancer Center
Publications - 193
Citations - 59407
Keith A. Baggerly is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Ovarian cancer. The author has an hindex of 65, co-authored 192 publications receiving 50803 citations. Previous affiliations of Keith A. Baggerly include University of Texas Health Science Center at Houston & Harvard University.
Papers
More filters
Journal ArticleDOI
Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways.
Jai-Hyun Kim,Tomasz Tuziak,Limei Hu,Zhi Wang,Jolanta Bondaruk,Mi Sook Kim,Gregory N. Fuller,Colin P.N. Dinney,H. B. Grossman,Keith A. Baggerly,Wei Zhang,Bogdan Czerniak +11 more
TL;DR: Tumors characterized by the low expression of e-cadherin and the high expression of DNA α-topoisomerase II had a high propensity for distant metastasis and were associated with poor survival, and genes controlling cellular and stromal interactions were altered in the nonpapillary cancer.
Journal ArticleDOI
Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma.
Lin Yang,H. Wang,Stephen Kornblau,David Graber,Nianxiang Zhang,Jairo Matthews,Michael Wang,Donna M Weber,Sheeba K. Thomas,Jatin J. Shah,Li Zhang,Gary Lu,Ming Zhao,Ramya Muddasani,Suk Young Yoo,Keith A. Baggerly,Robert Z. Orlowski +16 more
TL;DR: The data support the conclusion that ZKSCAN3 induction represents a mechanism by which myeloma cells can induce cyclin D2 dysregulation, and contribute to disease pathogenesis.
Journal ArticleDOI
Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.
Rebecca L. Stone,Keith A. Baggerly,Guillermo N. Armaiz-Pena,Yu Kang,Angela Sanguino,Duangmani Thanapprapasr,Heather J. Dalton,Justin Bottsford-Miller,Behrouz Zand,Rehan Akbani,Lixia Diao,Alpa M. Nick,Koen DeGeest,Gabriel Lopez-Berestein,Robert L. Coleman,Susan K. Lutgendorf,Anil K. Sood +16 more
TL;DR: FAK may be a unique therapeutic target in EOC given the dual anti-angiogenic and anti-metastatic potential of FAK inhibitors.
Journal ArticleDOI
Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis.
TL;DR: Establishing one epithelial and two mesenchymal cell lines from ascites of a bladder cancer patient demonstrated that the epithelial cells with surface expression of PD-L1, E-cadherin, CD24, and VEGFR2 rapidly formed tumors outside the primary tumor microenvironment in nude mice, exhibited signatures of immune evasion, increased stemness, increased calcium signaling, transformation, and novel E-c cadherin–RalBP1 interaction.
Journal ArticleDOI
Targeting Src and tubulin in mucinous ovarian carcinoma
Tao Liu,Wei Hu,Heather J. Dalton,Hyun Jin Choi,Jie Huang,Yu Kang,Sunila Pradeep,Takahito Miyake,Jian H. Song,Yunfei Wen,Chunhua Lu,Chad V. Pecot,Justin Bottsford-Miller,Behrouz Zand,Nicholas B. Jennings,Cristina Ivan,Gary E. Gallick,Keith A. Baggerly,David G. Hangauer,Robert L. Coleman,Michael Frumovitz,Anil K. Sood +21 more
TL;DR: The results showed that targeting both the Src pathway and tubulin with KX-01 significantly inhibited tumor growth in preclinical mucinous ovarian cancer models, suggesting that this may be a promising therapeutic approach for patients with mucous ovarian carcinoma.